Cancer therapy using nanoformulated substances: Scientific, regulatory and financial aspects

Expert Review of Anticancer Therapy

Volumn 15, Issue 10, 2015, Pages 1233-1255

  Alphandéry, Edouard ^a,b   Grand Dewyse, Pierre ^a   Lefèvre, Raphael ^a,c   Mandawala, Chalani ^a,d   Durand Dubief, Mickael ^a  

^a Nanobacterie   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DE PHYSIQUE DU GLOBE DE PARIS   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

cancer; nanodrug; nanoformulated drug; nanoformulation; nanomedicine; nanooncology; nanoparticle; nanopharmaceuticals

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CAMPTOTHECIN; CURCUMIN; DENILEUKIN DIFTITOX; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GENDICINE; GOLD NANOPARTICLE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUPRORELIN; LIPOSOME; MIFAMURTIDE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGFILGRASTIM; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN E7; PROTEIN P53; RECEPTOR ANTIBODY; TRASTUZUMAB EMTANSINE; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; NANOPARTICLE;

CANCER THERAPY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TOXICITY; FINANCE; HUMAN; LEGAL ASPECT; MEDICAL DEVICE; NANOMEDICINE; PATENT; REVIEW; ANIMAL; CHEMISTRY; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG DESIGN; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; SOLUBILITY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG AND NARCOTIC CONTROL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; HUMANS; NANOPARTICLES; NEOPLASMS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84942508355     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1086647     Document Type: Review

References (162)

1. Thako AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin 2013; 63: 395-418
2. Weissig V, Pettinger TK, Murdoch N. Nanopharmaceuticals (part I): products on the market. Int J Nanomedicine 2014; 9: 4357-73
3. Silverman JA, Deitcher SR. Marqibo (vincristine sulfate liposome) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol 2013; 71: 555-64
4. Harrison TS, Lyseng-Williamson KA. Vincrinstine sulfate liposome injection. BioDrugs 2013; 27: 69-74
5. Deitcher OR, Glaspy J, Gonzalez R, et al. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk 2014; 14 (3): 197-202
6. Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of Vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-cell lymphoma or Mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk 2014; 14 (1): 37-42
7. Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily preatreaed patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 2009; 115 (15): 3475-82
8. Batist GB, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cylophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19 (5): 1444-54
9. Leonard RCF, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracyline chemotherapy: Focus on liposomal doxorubicin (MyocetTM). Breast 2009; 18: 218-24
10. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94 (1): 25-36
11. Mross K, Niemann B, Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004; 54: 514-24
12. Amadori D, Milandri C, Comella G, et al. A Phase I/II trial of non-pegylated liposomal doxorubin, docetaxel and trastuzumab as first-line treatment in HER-2 positive locally advanced or metastatic breast cancer. Eur J Cancer 2011; 47: 2091-8
13. Del Barco S, Colomer R, Calvo L, et al. Non-pegylated doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res. Treat 2009; 116: 351-8
14. Ciolli S, Leoni F, Casini C, et al. The addition of liposomal doxorubicin to borteomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008; 141: 814-19
15. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-Related non-hodgkins lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22 (13): 2662-70
16. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. Ann Oncol 2010; 21: 1492-9
17. Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracylines. Hematol Oncol 2007; 25: 198-203
18. Stroppa E, Bertuzzi A, Di Comite G, et al. Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs 2010; 28: 834-8
19. Doxil product information, manufactured for Janssen Products, LP, Horsham, PA 19044, printed in USA
20. ®-The first FDA-approved nano-drug: Lessons learned. J Control Release 2012; 160: 117-34
21. Leonard RCF, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (MyocetTM. Breast 2009; 18: 218-24
22. ® and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia 2005; 21 (4): 333-47
23. El-Rayes B, Ibrahim D, Shields AF, et al. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Investgational New Drugs 2005; 23: 57-62
24. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncol 2006; 9: 393-403
25. ® pharmacokinetics. Int J Cancer 2004; 109: 442-8
26. Gill PS, Espina BM, Muggia F, et al. Phase I/II and Pharmacokinetic Evaluation of Liposomal Daunorubicin. J Clin Oncol 1995; 13: 996-1003
27. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leukemia & Lymphoma 2005; 46 (6): 795-802
28. Kapsers GJL, Zimmermann M, Reinhardt D, et al. Improved outcome in pedriatic relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J Clin Oncol 2013; 31 (5): 599-607
29. ®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Annal. Hematol 2009; 88: 151-8
30. Candoni A, Michelutti A, Simeone E, et al. Efficacy of liposomal daunorubicin and cytarabine as reinduction cgemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol 2006; 77: 293-9
31. Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008; 143: 681-9
32. Russo D, Piccaluga PP, Michieli M, et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol 2002; 81: 462-6
33. Hempel G, Reinhardt D, Creutzig U, et al. Population pharmacokinetics of liposomal daunorubicin in children. Clin. Pharmacol 2003; 56: 370-7
34. OByrne KJ, Thomas AL, Sharma RA, et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002; 87: 15-20
35. McTiernan A, Whelan J, Leahy M, et al. A Phase II nonrandomized open-label study of liposomal daunorubicin (Daunoxome) in advanced soft tissue sarcoma. Sarcoma 2006; ID 41080: 1-5
36. Mitchell PLR, Marlton P, Grigg A, et al. A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 2008; 49 (5): 924-31
37. Chen PY, Ozawa T, Drummond DC, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-oncol 2013; 15 (2): 189-97
38. Ko AH, Tempero MA, Shan Y-S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British Journal of Cancer 2013; 109: 920-5
39. Website of the company Merrimack. Available from: www.merrimackpharma.com/pipeline/MM-302
40. Frampton JE. Mifamurtide, a review of its use in the treatment of osteosarcoma. Adis Drug Evaluation 2010; 12 (3): 141-53
41. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. 2008; 57: 517-30
42. Poon RTP, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. 2009; 10 (2): 333-43
43. Thomas MB, Jaffe D, Choti MM, et al. hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 2010; 28 (25): 3994-4005
44. Notice of depocyte. Available from: www.ema.europa.eu/docs/fr-FR/document-library/EPAR---Product-Information/human/000317/WC500035649.pdf
45. ® ABI-007) in the treatment of breast cancer. Inter J Nanomed 2009; 4: 99-105
46. Bawarski WE, Chidlowsky E, Bharali DJ, et al. Emerging nanopharmaceuticals. Nanomedicine 2008; 4: 273-82
47. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III. trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23 (31): 7794-803
48. Braeckman J, Michielsen D. Efficacy and olerability of 1- and 3- month leuprorelin acetate depot formulation (Eligard/Depot-Eligard) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014; 3: 477-83
49. Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a bried review of history, molecular genetics, animal models and novel therapeutic strategies. Arch. Immunol. Ther. Exp 2013; 61: 25-41
50. Ishii H, Furuse J, Nagase M, et al. A Phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma. Jpn J Clin Oncol 2003; 33: 570-3
51. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6: 688-701
52. Rokx C, Van der Ende ME, Verbon A, et al. Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 patients. HIV/AIDS 2013; 57: 1497-9
53. Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162: 783-91
54. Go RS, Lee SJ, Shin D, et al. ECOG Phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma over-expressing basic fibroblast growth factor (E2602). Clin Cancer Res 2013; 19: 6597-604
55. Riker AI, Rossi GR, Masih P, et al. Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients. Ochsner J 2014; 14: 164-74
56. Annual report of bind therapeutic. Available from: http://ir.bindtherapeutics.com/annuals.cfm
57. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. PNAS 2006; 103 (16): 6315-20
58. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. PNAS 2008; 105 (7): 2586-91
59. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4 (128): 1-11
60. Eliasof S, Lazarus D, Peters CG, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. PNAS 2013; 110 (37): 15127-32
61. Gaur S, Chen L, Yen T, et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for treatment of gastric cancer. Nanomedicine 2012; 8: 721-30
62. Svenson S, Wolfgang M, Hwang J, et al. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 2011; 153: 49-55
63. Young C, Schluep T, Hwang J, et al. CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in clinical development. Current Bioactive Compounds 2011; 7: 8-14
64. Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31: 986-1000
65. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12: 1317-24
66. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther 2009; 9 (1): 111-19
67. Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005; 5 (12): 1635-46
68. Willis F, Pettengell R. Pegfilgrastim. Expert Opin Biol Ther 2002; 2 (8): 985-92
69. Morishita M, Leonard RC. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Exp Opin Biol Ther 2008; 8 (7): 993-1001
70. Eliasof S, Lazarus D, Peters CG, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. PNAS 2013; 110 (37): 15127-32
71. Goel R, Swanlund D, Coad J, et al. TNF-α-based accentuation in cryoinjury-dose, delivery, and response. Mol Cancer Ther 2007; 6 (7): 2039-47
72. Pedro RN, Thekke-Adiyat T, Goel R, et al. Use of tumor necrosis factor-alpha-coated gold nanoparticles to enhance radiofrequency ablation in a translational model of renal tumors. Urology 2010; 76 (2): 494-8
73. Visaria RK, Griffin RJ, Williams BW, et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-α delivery. Mol Cancer Ther 2006; 5 (4): 1014-20
74. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: A novel nanoparticle vector for tumor directed. Drug Deliv 2004; 11: 169-83
75. Diagaradjane P, Shetty A, Wang JC, et al. Modulation of in Vivo Tumor Radiation Response via Gold Nanoshell-Mediated Vascular-Focused Hyperthermia: Characterizing an Integrated Antihypoxic and Localized Vascular Disrupting Targeting Strategy. Nano Lett 2008; 8: 1492-500
76. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. PNAS 2003; 100 (23): 13549-4
77. Puvabakrishnan P, Park J. Near-infrared narrow-band imaging of gold/silica nanoshells in tumors. J Biomed Opt 2009; 14 (2): 024044-1-6
78. Stern JM, Stanfield J, Kabbani W, et al. Selective Prostate Cancer Thermal Ablation With Laser Activated Gold Nanoshells. J Urol 2008; 179: 748-53
79. Hainfeld JF, Dilmanian FA, Slatkin DN, et al. Radiotherapy enhancement with gold nanoparticles. Pharm Pharmacol 2008; 60: 977-85
80. Hainfeld JF, Dilmanian FA, Zhong Z, et al. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol 2010; 55: 3045-59
81. Hainfeld JF, Smilowitz HM, OConnor M, et al. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Future Medicine 2013; 8 (10): 1601-9
82. Hainfeld JF, OConnor MJ, Lin P, et al. Infrared-transparent gold nanoparticles converted by tumors to infrared absorbers cure tumors in mice by photothermal therapy. Plosone 2014; 9 (2): e88414
83. Jordan A, Waldoefner N, Decken K, Scholz R. inventors Nanoparticle/Active ingredient conjugates. United States patent. US 20080268061; 2006
84. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007; 81: 53-60
85. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103: 317-24
86. Maggiorella L, Barouch G, Devaux C, et al. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol 2012; 8 (9): 1167-81
87. Alphandéry E, Faure S, Seksek O, et al. Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy. ACSNano 2011; 5 (8): 6279-96
88. Alphandéry E. Perspective of breast cancer thermotherapies. J Cancer 2014; 5 (6): 472-9
89. Alphandéry E. Application of magnetosomes synthesized by magnetotactic bacteria in medicine. Front Bioeng bio 2014; 2: 5-6
90. Alphandéry E, Chebbi I, Guyot F, et al. Use of bacterial Magnetosomes in the magnetic hyperthermia treatment of tumours: A review. Int J Hyperthermia 2013; 29 (8): 801-9
91. Alphandéry E, Lijeour L, Lalatonne Y, et al. Different signatures between chemically and biologically synthesized nanoparticles in a magnetic sensor: A new technology for multiparametric detection. Sensors and Actuators B 2010; 146: 786-90
92. Alphandéry E, Carvallo C, Menguy N. Chains of cobalt doped magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy. J Phys Chem C 2011; 115: 11920-4
93. Alphandéry E, Faure S, Raison L. Heat production by bacterial Magnetosomes exposed to an oscillating magnetic field. J Phys Chem C 2011; 115: 18-22
94. Alphandéry E, Amor M, Guyot F, et al. The effect of iron-chelating agents on Magnetospirillum magneticum strain AMB-1: stimulated growth and magnetosome production and improved magnetosome heating properties. Appl Microbiol Biotechnol 2012; 96: 663-70
95. Alphandéry E, Guyot F, Chebbi I. Preparation of chains of magnetosomes from magnetospirillum magneticum strain AMB-1 magnetotactic bacteria, yielding efficient treatment of tumors using magnetic hyperthermia. Inter J Pharmaceutics 2012; 434: 444-52
96. Sadeghi S, Olevsky O, Hurvitz S. Profiling and targeting HER-2-positive breast cancer using trastuzumab emtansine. Pharm Person Med 2014; 7: 329-38
97. Ansell S M, Tang H, Kurtin P J, et al. Denileukin Diftitox in Combination with Retuximab for Previously Untreated Follecular B-cell Non-Hodgkins Lymphoma. Leukemia 2012; 26: 1046-52
98. Chen GX, Zhang S, He XH. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets and Therapy 2014; 7: 1901-9
99. Li J, Pan J, Zhu X, et al. Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation. Chin J Cancer Res 2013; 25: 715-21
100. Mathur M, Govind V. Role of nanoparticles for production of smart herbal drug-An overview. Ind J Nat Pro Res 2013; 4: 329-38
101. Weissig V, Pettinger T, Murdock N. Nanopharmaceuticals (part I): products on the market. Int J Nanomedicine 2014; 9: 4357-73
102. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012; 17: 71-80
103. Koo OM, Rubinstein I, Onyuksel H. Campthotecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 2005; 1: 77-84
104. Ucisik MH, Kupcu S, Schuster B, et al. Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin. J Nanobiotechnology 2013; 11: 37
105. Markovsky E, Baabur-Cohen H, Eldar-Boock A, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012; 161: 446-60
106. Bawarski WE, Chidlowsky E, Bharali DJ, et al. Emerging nanopharmaceuticals. Nanomedicine 2008; 4: 273-82
107. Fourmy D, Carrey J, Gigoux V. Targeted nanoscale magnetic hyperthermia: challenges and potentials of peptide-based targeting. Nanomedicine 2015; 10: 893-6
108. Kievit FM, Zhang M. Surface engineering of Iron Oxode Nanoparticles for targeted Cancer Therapy. Acc Chem Res 2011; 44: 853-62
109. Wieder ME, Hone DC, Cook MJ, et al. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a Trojan horse. Photochemical and Photobiological Sciences 2006; 5: 727-34
110. Onoue S, Yamada S, Chan H-K. Nanodrugs: pharmacokinetics and safety. International J of Nanomedicine 2014; 9: 1025-37
111. Thako AS, Gambhir SS. Nanooncology: The Future of Cancer Diagnosis and Therapy. CA Cancer J Clin 2013; 63: 395-418
112. Ehmann F, Sakai-Kato K, Duncan R, et al. Next-generation nanomedicines and nanosimilars: EU regulators initiatives relating to the development and evaluation of nanomedicines. Future Medicine 2013; 8: 849-56
113. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012; 14: 282-95
114. Jordan A, Scholz R, Maierhauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006; 78: 7-14
115. Schroeder Handy E, Ivkov R, Ellis-Busby D, Foreman A. inventors Triton Biosystem Inc., assignee. Thermotherapy via targeted delivery of nanoscale magnetic particles. United States patent. US0028071; 2003
116. Jordan A, Waldoefner N, Decken K, Scholz R. inventors Nanoparticle/Active ingredient conjugates. United States patent. US 20080268061; 2006
117. Waldoefner N, Stief K. inventors Magnetic transducers. United States patent. US 20110052609; 2010
118. Thiesen B, Jordan A. inventors Magforce Nanotechnologies AG. Assignee. Implantable products comprising nanoparticles. United States patent. US 20110223255; 2009
119. Alphandéry E, Faure S, Chebbi I. Nanobacterie, assignee. Treatment of cancer or tumors induced by the release of heat generated by various chains of Magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field. United States patent. US 20120302819; 2010
120. Alphandéry E, Chebbi I. UPMC and CNRS, assignee. Use of at least one iron chelate introduced in the bacterial growth medium to stimulate the growth of these bacteria. WO153247; 2012
121. Hainfeld JF. inventor Nanoprobes Inc., assignee; Methods and composition for increasing infrared absorptivity of a target. US0279946; 2008
122. Liu W, Hainfeld JF. inventor Nanoprobes Inc, assignee; 5 nm Nickel-NTA-Gold Nanoparticles. US0244075; 2012
123. Levy L, Hochepied JF, Balencie J, et al. inventors; Nanobiotix, assignee, Activatable particles, preparations and uses. W0120590; 2005
124. Lévy L, Boussaha AK, Panak EA. inventors Nanobiotix assignee, Nanoparticles comprising an intracellular targeting element and preparation and use thereof. WO 2006/051198; 2004
125. Levy L, Pottier A, Rouet A, et al. inventors Nanobiotix, assignee, Inorganic nanoparticles, preparation and uses thereof. WO 2009147214; 2008
126. Lévy L, Pottier A, Puoi L, Maggiorella L. inventors Nanobiotix, assignee, Metallic nanoparticles, preparation and uses thereof. WO 2011003999; 2009
127. Pottier A, Lévy L, Meyre ME. inventors Nanobiotix assignee, Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof. WO 2013087920; 2012
128. Krishnan S, Diagaradjane P, Schwartz JA, Wang JC. inventors University of Texas and Nanospectra, assignee. Treatment of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy. US0197295; 2013
129. Krishanan S, Diagaradjane P, Goodrich G. inventors The University of Texas and Nanospectra Inc, assignee. Enhancement of radiation therapy by targeted high-z nanoparticles. WO 2011127061; 2010
130. Hainfeld JF, Slatkin DN. inventors NanoProbes Inc; Methods of enhancing radiation effects with metal nanoparticles. US0186060; 2009
131. Mei X, Qinggwei J, Yu W. inventors Celsion Corp, assignee, Thermosensitive liposomes containing therapeutic agents. US0200665; 2011
132. Hong K, Drummond DC, Kirpotin D. inventors Merrimack pharmaceuticals Inc, assignee. Liposome useful for drug delivery. US0122081; 2013
133. Cheng J, Davis ME, Khin KT. inventors Cerulean Pharma Inc, assignee; Cyclodextrin-based polymers for therapeutic delivery. US0190450; 2013
134. Cheng J, Davis ME, Khin KT. inventors Cerulean Pharma Inc., assignee. Cyclodextrin-based polymers for therapeutics delivery. US0129665; 2013
135. Figueiredo M, Peeke E, Dewitt D, et al. inventors Bind Therapeutics Inc., assignee. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same. US0178475; 2014
136. Zale SE, Troiano G, Ali MM, et al. Bind Therapeutics Inc, assignee. Therapeutic polymeric nanoparticles with mitor inhibitors and methods of making and using same. US0186453; 2014
137. Jadhav N, Powar T, Shinde S, Nadaf S. Herbal nanoparticles: A patent review. Asian journal of Pharmaceutics 2014; 8: 58-69
138. Bosetti R, Vereeck L. Future of nanomedicine obstacles and remedies. Nanomedicine 2011; 6: 747-55
139. Edison investment Research. "Magforce, accelerating on the US highway". 2014
140. Edison investment Research. "Nanobiotix, Good things come in small packages". 2013
141. Edison investment research. "BioAlliance Pharma Awaiting Onxeo". 2014
142. Vision and objective. Available from: www.pharmaengine.com
143. Transparency market research. "Nanomedicine market: global industry analysis, size, share, growth, trends and forecast 2013-2019". Available from: www.transparencymarketresearch.com. [Last accessed 1 August 2014]
144. Werner ME, Cummings ND, Sethi M, et al. Preclinical evaluation of genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Radiation Oncol 2013; 86: 463-8
145. Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel pegylated colloidal gold-rhTNF nanomedicine. Clin Cancer Research 2010; 16 (24): 6139-49
146. Schwartz JA, Price RE, Gill-Sharp KL, et al. Selective nanoparticle-directed ablation of the canine prostate. Lasers Surg Med 2011; 43: 213-20
147. Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: Feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007; 52: 1653-62
148. Vasievich EA, Chen W, Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine, Cancer Immun. Immunother 2011; 60: 629-38
149. Notice of Mepact. Available from: www.ema.europa.eu/docs/fr-FR/document-library/EPAR---Product-Information/human/000802/WC500026565.pdf
150. 2014 annual report of Merrimack. Available from: http://investors.merrimackpharma.com/secfiling.cfm?filingID=1193125-14- 82294&CIK=1274792
151. Notice of Marqibo. Available from: www.drugs.com/cdi/marqibo-injection.html
152. Notice of Depocyt. Available from: www.ema.europa.eu/docs/fr-FR/document-library/EPAR---Product-Information/human/000317/WC500035649.pdf
153. 2013 annual report of Bioalliance Pharma. Available from: www.onxeo.com/site/pdf/RA-2013-BioAlliancePharma-EN.pdf
154. Farma JM, Puhlmann M, Soriano PA, et al. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer 2007; 120: 2474-80
155. Bardhan R, Chen W, Bartels M, et al. Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo. Nano Lett 2011; 10: 4920-8
156. Young C, Schluep T, Hwang J, et al. CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Campthotecin in Clinical Development. Current Bioactive Compounds 2011; 7: 8-14
157. Frenkel V, Etherington A, Greene M, et al. Delivery of liposomal doxorubicin (doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Academic radiology 2006; p13 (4): 469-79
158. Hainfeld JF, Smilowitz HM, OConnor M, et al. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Future Med 2013; 8 (10): 1601-9
159. Rose PG, Blessing JA, Lele S, et al. Evaluation of pegylated doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Genecologie Oncol 2006; 102: 210-13
160. Willis F, Pettengell R. Pegfilgrastim. Exp Opinion Biol Ther 2002; 2: 985-92
161. Kaspers GJL, Zimmermann M, Reinhardt D, et al. Improved outcome in pedriatic relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM stdy group. J Clin Oncol 2013; 31: 599-607
162. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012; 7: 49-60